



Fax completed form to Navitus at: 855-668-8553  
For questions, please call: 877-908-6023

### TEXAS MEDICAID

### Drug Prior Authorization

### Monoclonal Antibodies: mepolizumab (NUCALA)

#### Request Information (required)

This request is:

- Expedited\* (Urgent)
- Standard (Non-Urgent)

\*Expedited means the standard review time may seriously harm the member's life, health, or ability to regain maximum function.

#### Member Information (required)

#### Prescriber Information (required)

Member Name:			Prescriber Name:		
Member Insurance ID #:			NPI # :		Specialty:
Date of Birth:			Office Phone:		
Member Phone:			Office Fax:		
Member Street Address:			Office Street Address:		
City:	State:	Zip:	City:	State:	Zip:

#### Please fill out the following information:

- Medication Requested (Name):  
(Go to #2)

2. Quantity Requested:  
(Go to #3)

3. Dose Requested (Strength):  
(Go to #4)

4. Dosing Instructions:  
(Go to #5)

**Required Criteria**

5. Provide primary diagnosis including ICD-10 code(s):  
(Go to #6)

6. Please indicate the requested drug's formulary status: \*(Formulary available at [www.txvendordrug.com](http://www.txvendordrug.com))

Non-Preferred Drug (NPD or NAP)

(Go to #7)

Preferred Drug (PDL)

(Go to #10)

No Status, Drug is not in a Market Basket

(Go to #10)

N/A as this request is for a CHIP/PERINATE member

(Go to #10)

Preferred Drug List (PDL) Criteria (required for non-preferred products)

7. Has the member failed a 30-day treatment trial with at least one (1) preferred agent in the last 180 days?

Yes

(Go to #10)

No

(Go to #8)

8. Is there a documented allergy or contraindication to preferred agents in this class?

Yes

(Go to #10)

No

(Go to #9)

9. Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions?

Yes

(Go to #10)

No (Deny)

(Go to #10)

Clinical Criteria (required)

10. Is the member greater than or equal to ( $\geq$ ) six (6) years of age?

Yes

(Go to #11)

No (Deny)

(Go to #11)

11. Does the member have a diagnosis of severe asthma in the last 730 days?

Yes

(Go to #12)

No

(Go to #13)

12. Does the member have a claim for an asthma controller medication in the last 90 days?

Examples of asthma controller medications include: ALVESCO, ARNUITY ELLIPTA, ASMANEX HFA, ASMANEX TWISTHALER, BREO ELLIPTA, budesonide (PULMICORT), DULERA, FLOVENT DISKUS, FLOVENT HFA, fluticasone-salmeterol (ADVAIR DISKUS/ADVAIR HFA, WIXELA), hydrocortisone, methylprednisolone (MEDROL), prednisolone (MILLIPRED), prednisolone, prednisone, QVAR REDIMALER, and SYMBICORT.

Yes

(Go to #21)

No (Deny)

(Go to #13)

13. Is the member greater than or equal to ( $\geq$ ) 12 years of age?

Yes

(Go to #14)

No (Deny)

(Go to #14)

14. Does the member have a diagnosis of hypereosinophilic syndrome (HES) in the last 730 days?

Yes

(Go to #18)

No

(Go to #15)

15. Does the member have a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA) in the last 730 days?

Yes

(Go to #17)

No

(Go to #16)

16. Does the member have a diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP) in the last 730 days?

Yes

(Go to #17)

No (Deny)

(Go to #17)

17. Is the member greater than or equal to ( $\geq$ ) 18 years of age?

Yes, and the member has a diagnosis of EGPA

(Go to #18)

Yes, and the member has a diagnosis of CRSwNP

(Go to #20)

No (Deny)

(Go to #18)

18. Has the member had a trial of oral glucocorticoid therapy in the last 45 days, or is oral glucocorticoid therapy contraindicated?

Examples of oral glucocorticoid therapies include: hydrocortisone, methylprednisolone (MEDROL, MILLIPRED), prednisolone, and prednisone.

**Yes**

(Go to #19)

**No (Deny)**

(Go to #19)

19. Has the member had a trial of cyclophosphamide, azathioprine, methotrexate (OTREXUP, RASUVO, TREXALL, XATMEP) or leflunomide (ARAVA) in the last 90 days, or is a trial of these medications contraindicated?

**Yes**

(Go to #21)

**No (Deny)**

(Go to #20)

20. Will the member have concurrent therapy with intranasal corticosteroids?

Examples of intranasal corticosteroids include: azelastine-fluticasone (DYMISTA), BECONASE, AQ, budesonide, flunisolide, fluticasone propionate (XHANCE), mometasone furoate (NASONEX), OMNARIS, QNASL, and triamcinolone nasal spray.

**Yes**

(Go to #21)

**No (Deny)**

(Go to #21)

21. Does the member have a diagnosis of helminth infection in the last 180 days?

**Yes**

(Go to #22)

**No**

(Go to #23)

22. Does the member have a claim for an anthelmintic agent in the last 180 days?

Examples of anthelmintic agents include: albendazole (ALBENZA), EMVERM, ivermectin (STROMEKTOL), and praziquantel (BILTRICIDE).

Yes

(Go to #23)

No (Deny)

(Go to #23)

23. Is the requested quantity greater than (>) one (1) syringe per 30 days for members with asthma or chronic rhinosinusitis with nasal polyps (CRSwNP) **OR** greater than (>) three (3) syringes per 30 days for members with eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome (HES)?

Yes (Deny)

(Go to #24)

No (Approve - 365 days)

(Go to #24)

Additional Information

24. Please provide any additional information we should consider (or attach any supporting documents):  
(END)

**Submission Information (required)**

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**\*\* PLEASE FAX COMPLETED FORM TO: 855-668-8553 \*\***

Drug Prior Authorization

Monoclonal Antibodies: mepolizumab (NUCALA)

---

If criteria not met, submit chart documentation with form citing complex medical circumstances.

For questions, please call Customer Care at 877-908-6023

For questions, please call Navitus Customer Care at 1-877-908-6023.